Cash Position: Ended the quarter with $509 million in cash. Cash Burn: $118 million during Q1 2025, including cash operating expenses and capital expenditures. Cash Runway: Expected to extend into mid ...

Recursion Pharmaceuticals (NASDAQ: RXRX), a $3.03 billion market cap biotech company, reported a larger-than-expected loss for Q4 2024, with an EPS of -0.53 compared to the forecasted -0.41. The ...

Recursion Pharmaceuticals reported its second-quarter 2025 earnings with revenue significantly surpassing expectations, while earnings per share (EPS) fell short. The company posted an actual EPS of ...